Promising new attack on tough breast cancer brain metastases
NCT ID NCT06238921
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding two drugs (sacituzumab govitecan and zimberelimab) to precise brain radiation can help people with metastatic triple negative breast cancer that has spread to the brain. The trial will enroll 31 adults and compare the combination against sacituzumab govitecan alone. Researchers will monitor safety and how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab govitecan (Trodelvy) and zimberelimab
What this could lead to
If successful, this combination could offer a new treatment option that helps control both brain and body tumors in people with metastatic triple negative breast cancer.
What could go wrong
This is an early-phase trial with only 31 participants, so results may not apply to everyone. The added drugs and radiation may cause serious side effects like neurological toxicity or radionecrosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••